Inhibikase Therapeutics, Inc.
IKTHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeInhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a. The company carries a $348.8M market cap, placing it firmly in the small-cap category. It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PAH) was designed to improve areas of the molecule that might play a role in the gastrointestinal side effects associated with imatinib, while maintaining systemic exposure and efficacy through oral administration.
Market Cap
$348.8M
Beta
0.96
P/E (TTM)
—
P/E (Fwd)
-5.78
EPS (TTM)
$-0.44
EPS (Fwd)
$-0.43
ROE
-52.0%
ROA
-32.8%
Cash
$159.0M
Total Debt
$0
Free CF
-$22.1M
52W Change
50.6%
Annual Financials
Cash vs Debt
Where IKT stands vs its 150-day and 200-day moving averages
As of the August 18, 2026 close, IKT finished 27.13% above its 150-day moving average ($1.88) and 32.04% above its 200-day moving average ($1.81). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is IKT overbought or oversold?
At the August 18, 2026 close, IKT's RSI(14) was 55.4, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Inhibikase Therapeutics, Inc. reports $159.0M in cash and $0 in total debt. The company is burning cash, with free cash flow at -$22.1M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -52.0% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing IKT's risk profile alongside its fundamentals and technical indicators provides a more complete picture.